Inolife primes ADW to distribute Inojex

 - 
Tuesday, April 17, 2018

TORONTO – Inolife R&D has entered into a letter of intent with ADW Diabetes for the distribution of its Inojex, a patented and FDA-cleared needle-free injection device. With ADW as a new partner, Inolife will have strategic access to one of the biggest insulin markets in the world, according to a press release. “By connecting innovative needle-free insulin delivery technologies to ADW’s diabetic community, we will create new opportunities and synergies that otherwise would not have been available to our companies,” said Michael Wright, president and CEO of Inolife. “Partnering with ADW fits perfectly into our vision that every individual should have the opportunity to receive healthcare that is empowering, safe and respectful.” Company officials say the fear of needles is a leading reason why people with diabetes do not stay on track with their care team’s recommendations for optimum blood glucose management. “Inolife solves that problem,” said Michael Maguire, president and CEO of ADW. “ADW is excited to team up with Inolife so we can delivery comfort and ease to anyone with diabetes.”